CONCLUSIONS: In this novel comparison of fertility outcomes between men with CF and CBAVD, those with CF had lower sperm quality with MESA, were more likely to require rescue TESE, and experienced a lower fertilization rate with ICSI compared with CBAVD patients. In addition to causing OA, homozygous CFTR mutations, particularly homozygous delta F508 mutations, also significantly impair spermatogenesis and sperm function.
INTRODUCTION AND OBJECTIVES:
There is robust data demonstrating the relationship between postoperative opioid prescriptions and the risk of chronic opioid dependence. Conversely, there are few guidelines for what prescriptions are appropriate in the postoperative period. Vasectomy is the most common non-diagnostic operation performed by US urologists. The 2010 AUA Guidelines on Vasectomy do not make a recommendation for opioid prescribing post-procedure, which may result in variation in (and possibly overprescribing of) opioids. We sought to determine urologist patterns of opioid prescribing after vasectomy.
METHODS: We designed a 12-question survey that assessed vasectomy experience and post-vasectomy opioid prescriptions. Using the American Medical Association Physician Masterfile database, this was sent to 3000 urologists via e-mail. All responses were anonymous.
RESULTS: 133 responses were received (4.4% response rate). 42.9% of urologists performed 6-10 vasectomies per month, 30.8% performed 0-5 per month and 18% performed 11-15 per month. 86.5% performed vasectomies with the patient fully awake or with oral sedation. 51.5% prescribed opioids for post-procedural analgesia after vasectomy, and 48.5% did not. 77.4% encouraged men to use antiinflammatories as their primary modality of pain control postvasectomy. Of urologists who prescribed opioids (oxycodone 5 mg with or without acetaminophen), 67.4% prescribed 5-10 tabs, 31.4% prescribed 11-20 tabs, 1.2% prescribed 21-30 tabs and none prescribed >31 tabs. 50.4% of urologists reported having no idea of what percentage of patients actually used the narcotics that they were written for; 23% said that <25% of patients used their prescribed narcotics and 16.8% said that 26-50% of patients used their narcotics. Finally, 44.7% of urologists stated that practice guidelines guiding post-vasectomy opioid pain control would be helpful to their practice.
CONCLUSIONS: Most urologists perform 6-10 vasectomies per month, generally with the patient awake or with oral sedation. More than three-fourths encourage non-narcotics as the primary means of postprocedure analgesia. While prescribing opioids after vasectomies is common, most urologists do not know how many of their patients actually use these medications. Given the strong relationship between the opioid epidemic and post-procedural opioid prescriptions, practice guidelines on opioid prescribing after vasectomy may help to guide urologists and minimize the number of unnecessary narcotics being prescribed.
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PD34-07 A NOVEL MICROFLUIDIC DEVICE TO IMPROVE SPERM SEARCHING IN MICRODISSECTION TESE SAMPLES
Alex Jafek*, Haidong Feng, Timothy Jenkins, Kenneth Aston, Douglas Carrell, Bruce Gale, Raheel Samuel, Jim Hotaling, Salt Lake City, UT INTRODUCTION AND OBJECTIVES: Microdissection TESE (mTESE) is currently the gold standard for sperm retrieval in men with non-obstructive azoospermia. Currently, the procedure relies on an embryologist manually searching for sperm for 4-12 hours. We sought to determine whether a novel microfluidic device could purify mTESE samples prior to sperm retrieval from tissue specimens. The goal was to determine if the device could remove all contaminating debris without loss of sperm and reduce the sample volume using a novel microfluidic device.
METHODS: Participants were recruited from our Andrology clinic and were required to adhere to standard collection instructions. We simulated mTESE samples using a combination of washed sperm cells at low concentrations and somatic cells. These simulated mTESE samples were processed through a microfluidic spiral channel device which employs Dean flow to create a morphology-based separation between sperm and other cell types. The output of the device was sorted in to four portions of equal volume which were individually counted for sperm and blood cell concentration.
RESULTS: Our results indicate that our microfluidic device is capable of improving the search by both removing contaminating debris and reducing the sample volume. In a single pass of the spiral channel, the vast majority of somatic cells are sorted to a single outlet of the device away from the sperm. Our results show that the volume can be reduced by 25% while removing 68% of the blood cells in the sample. This is done while 98% of the sperm are retained in the selected portion as shown in Figure 1 . CONCLUSIONS: Our microfluidic device is capable of significantly improving the search for sperm from mTESE samples by removing 25% of the sample volume and 68% of the blood cells while retaining 98% of the sperm. We hypothesize that providing a smaller, cleaner sample to embryologists will allow them to be more successful in their search for sperm in a testicular biopsy sample and are currently working to acquire the samples and data necessary to prove this.
